Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Cancer Immunology, Immunotherapy
Published in: Cancer Immunology, Immunotherapy 3/1998

01-10-1998 | ORIGINAL ARTICLE

Neo-adjuvant chemo-(immuno-)therapy of advanced squamous-cell head and neck carcinoma: a multicenter, phase III, randomized study comparing cisplatin + 5-fluorouracil (5-FU) with cisplatin + 5-FU + recombinant interleukin 2

Authors: Giovanni Mantovani, Vittorio Gebbia, Mario Airoldi, Cesare Bumma, Paolo Contu, Alessandro Bianchi, Massimo Ghiani, Daniela Dessì, Elena Massa, Luigi Curreli, Biancarosa Lampis, Paola Lai, Carlo Mulas, Antonio Testa, Ernesto Proto, Gabrio Cadeddu, Giorgio Tore

Published in: Cancer Immunology, Immunotherapy | Issue 3/1998

Login to get access
Metadata
Title
Neo-adjuvant chemo-(immuno-)therapy of advanced squamous-cell head and neck carcinoma: a multicenter, phase III, randomized study comparing cisplatin + 5-fluorouracil (5-FU) with cisplatin + 5-FU + recombinant interleukin 2
Authors
Giovanni Mantovani
Vittorio Gebbia
Mario Airoldi
Cesare Bumma
Paolo Contu
Alessandro Bianchi
Massimo Ghiani
Daniela Dessì
Elena Massa
Luigi Curreli
Biancarosa Lampis
Paola Lai
Carlo Mulas
Antonio Testa
Ernesto Proto
Gabrio Cadeddu
Giorgio Tore
Publication date
01-10-1998
Publisher
Springer-Verlag
Published in
Cancer Immunology, Immunotherapy / Issue 3/1998
Print ISSN: 0340-7004
Electronic ISSN: 1432-0851
DOI
https://doi.org/10.1007/s002620050515

Other articles of this Issue 3/1998

Cancer Immunology, Immunotherapy 3/1998 Go to the issue

ORIGINAL ARTICLE

The effect of recombinant human granulocyte/macrophage-colony-stimulating factor (rHu GM-CSF) and rHu G-CSF administration on neutrophil chemiluminescence assay in patients following cyclic chemotherapy

ORIGINAL ARTICLE

Pharmacokinetics and biodistribution of radioimmunoconjugates of anti-CD19 antibody and single-chain Fv for treatment of human B-cell Malignancy

ORIGINAL

Adjuvant treatment of breast cancer: A pilot immunochemotherapy study with CMF, interleukin-2 and interferon alpha

ORIGINAL ARTICLE

Activation of EGF receptor family members suppresses the cytotoxic effects of tumor necrosis factor-α

ORIGINAL ARTICLE

Antitumor activity exhibited by Fas ligand (CD95L) overexpressed on lymphoid cells against Fas+ tumor cells

ORIGINAL ARTICLE

Pharmacological administration of granulocyte/macrophage-colony-stimulating factor is of significant importance for the induction of a strong humoral and cellular response in patients immunized with recombinant carcinoembryonic antigen
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits